Analysis on the potential effects of cost-sharing reduction payments and pass-through savings.
Here’s more on how proposed modifications to CMS’ Advance Notice Summary may affect reimbursement, payment growth rates, and regulation.
In light of breaking news, the pharma value chain is definitely ripe for disruption. Here's how health plans, employers, and drug companies can adjust to the new normal.
Healthcare coverage costs are rising for those unqualified for premium subsidies. Here are some important suggestions for policymakers.
Here are some greater implications and carrier considerations regarding draft regulation changes for association health plans.
The impact of one proposal the US Senate is considering to fund CSR payments.
Perceptions of behavioral health are evolving. Here’s why a multi-faceted approach to behavioral health brings more value to patients.
Oliver Wyman's analysis of small group market risk adjustment examines past formulas, models, and systems to predict the future.
Based on our analysis recently featured in the Wall Street Journal, the prevalence of no cost bronze coverage has increased significantly for 2018.
The compromise bill may help stabilize the once shaky ACA, but here’s why this bill still demands even greater change moving forward.